Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
JAMA Cardiol ; 7(3): 259-267, 2022 Mar 01.
Article in English | MEDLINE | ID: mdl-34935857

ABSTRACT

IMPORTANCE: Race and ethnicity have been studied as risk factors in cardiovascular disease. How risk factors, epicardial coronary artery disease, and cardiac events differ between Black and White individuals undergoing noninvasive testing for coronary artery disease is not known. OBJECTIVE: To assess differences in cardiovascular risk burden, coronary plaque, and major adverse cardiac events between Black and White individuals assigned to receive coronary computed tomography angiography (CCTA) or functional testing for stable chest pain. DESIGN, SETTING, AND PARTICIPANTS: A nested observational cohort study within the PROMISE trial was conducted at 193 outpatient sites in North America. A total of 1071 non-Hispanic Black (hereafter Black) and 7693 non-Hispanic White (hereafter White) participants with stable chest pain undergoing noninvasive cardiovascular testing were included. This analysis was conducted from February 13, 2015, to November 2, 2021. MAIN OUTCOMES AND MEASURES: The primary end point was the composite of death, myocardial infarction, or hospitalization for unstable angina over a median follow-up of 24.4 months. RESULTS: Among 1071 Black individuals (12.2%) (women, 646 [60.3%]; mean [SD] age, 59 [8] years) and 7693 White individuals (87.8%) (women, 4029 [52.4%]; mean [SD] age, 61.1 [8.4] years), Black participants had a higher cardiovascular risk burden (more hypertension and diabetes), yet there was a similarly low major adverse cardiovascular events rate over a median 2-year follow-up (32 [3.0%] vs 243 [3.2%]; P = .84). Sensitivity analyses restricted to the 79.8% (6993 of 8764) individuals with a normal or mildly abnormal noninvasive testing result and the 54.3% (4559 of 8396) not receiving statin therapy yielded similar findings. In comparison of Black and White individuals in the CCTA group (n = 3323), significant coronary stenosis (hazard ratio [HR], 7.21; 95% CI, 1.94-26.76 vs HR, 4.30; 95% CI, 2.62-7.04) and high-risk plaque (HR, 3.47; 95% CI, 1.00-12.06 vs HR, 2.21; 95% CI, 1.37-3.57) were associated with major adverse cardiovascular events in both Black and White patients. However, with respect to epicardial coronary artery disease burden, Black individuals had a less-prevalent coronary artery calcium score greater than 0 (45.1% vs 63.2%; P < .001), coronary stenosis greater than or equal to 50% (32 [8.7%] vs 430 [14.6%]; P = .001), and high-risk plaque (139 [37.6%] vs 1547 [52.4%]; P < .001). CONCLUSIONS AND RELEVANCE: The findings of this study suggest that, despite a greater cardiovascular risk burden in Black persons, rates of coronary artery calcium, stenosis, and high-risk plaque observed via CCTA were lower in Black persons than White persons. This result suggests differences in cardiovascular risk burden and coronary plaque in Black and White individuals with stable chest pain.


Subject(s)
Cardiovascular Diseases , Coronary Artery Disease , Coronary Stenosis , Plaque, Atherosclerotic , Calcium , Cardiovascular Diseases/complications , Cardiovascular Diseases/epidemiology , Chest Pain/etiology , Coronary Angiography/methods , Coronary Artery Disease/complications , Coronary Artery Disease/epidemiology , Coronary Stenosis/complications , Female , Heart Disease Risk Factors , Humans , Middle Aged , Plaque, Atherosclerotic/complications , Risk Factors
2.
Am Heart J ; 212: 1-12, 2019 06.
Article in English | MEDLINE | ID: mdl-30928823

ABSTRACT

BACKGROUND: People with HIV (PWH) have increased cardiovascular events, inflammation, and high-risk coronary atherosclerosis. Statin therapy has been shown to lower the risk of cardiovascular disease (CVD) in the general population, but whether this results from reductions in coronary atherosclerosis and is mediated by decreased inflammation remains unknown. METHODS: REPRIEVE is a randomized, placebo-controlled trial of pitavastatin calcium (4 mg/day) vs. placebo enrolling at least 7500 PWH between 40-75 years, on antiretroviral therapy (ART), with low to moderate traditional CVD risk. The Mechanistic Substudy of REPRIEVE (A5333s) is co-enrolling 800 participants from 31 US sites. These participants undergo serial contrast enhanced coronary computed tomography angiography (CCTA) and measurements of biomarkers of inflammation and immune activation at baseline and after 2 years of follow-up. The primary objectives are to determine the effects of pitavastatin on noncalcified coronary atherosclerotic plaque (NCP) volume, low attenuation plaque, and positive remodeling and on changes in immune activation and inflammation and to assess relationships between the two. Changes in CAD will be assessed in a standardized fashion by a core lab with expert readers blinded to time points and participant information; immune activation and inflammation assessment is also performed centrally. RESULTS: To date the Mechanistic Substudy has completed planned enrollment, with 805 participants. CONCLUSION: This study represents the first large, randomized, CCTA-based assessment of the effects of a primary prevention strategy for CVD on high-risk CAD, immune activation and inflammation among PWH. The study will assess pitavastatin's effects on coronary plaque, and the interrelationship of these changes with biomarkers of immune activation and inflammation in PWH to determine mechanisms of CVD prevention and improved outcomes in this population.


Subject(s)
Coronary Artery Disease/complications , Coronary Artery Disease/prevention & control , HIV Infections/complications , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Inflammation/prevention & control , Quinolines/therapeutic use , Adult , Aged , Anti-HIV Agents/therapeutic use , Biomarkers/blood , Computed Tomography Angiography , Coronary Angiography , Coronary Artery Disease/immunology , Double-Blind Method , Female , HIV Infections/drug therapy , HIV Infections/immunology , Humans , Male , Middle Aged , Plaque, Atherosclerotic/diagnostic imaging , Plaque, Atherosclerotic/prevention & control , Primary Prevention , Prospective Studies , Risk Factors
3.
Reprod Sci ; 23(6): 785-94, 2016 06.
Article in English | MEDLINE | ID: mdl-26614264

ABSTRACT

While live births resulting from assisted reproductive technology (ART) exceed 1% of total births annually, the effect of ART on fetal development is not well understood. Data have demonstrated that IVF leads to alterations in DNA methylation and gene expression in the placenta that may have long-term effects on health and disease. Studies have linked adverse neurodevelopmental outcomes to ART, although human studies are inconclusive. In order to isolate the peri-implantation environment and its effects on brain development, we utilized a mouse model with and without superovulation and examined the effect of adult behavior as well as adult cortical neuronal density. Adult offspring of superovulated dams showed increased anxiety-like behavior compared to offspring of naturally mated dams (P < .05). There was no difference in memory and learning tests between the 2 groups. The adult brains from offspring of superovulated recipients had fewer neurons per field compared to naturally mated control offspring (P < .05). In order to examine potential pathways leading to these changes, we measured messenger RNA and microRNA (miRNA) expression in fetal brains at E18.5. Microarray analysis found that miRNAs miR-122, miR-144, and miR-211, involved in regulation of neuronal migration and differentiation, were downregulated in brains of offspring exposed to a superovulated environment(P < .05). There was also altered expression of genes involved in neuronal development. These results suggest that the peri-implantation environment can affect neurodevelopment and can lead to behavioral changes in adulthood. Human studies with long-term follow-up of children from ART are necessary to further investigate the influence of ART on the offspring.


Subject(s)
Behavior, Animal , Cerebral Cortex/embryology , Cerebral Cortex/metabolism , Embryo Implantation , Neurons/metabolism , Superovulation/metabolism , Animals , Anxiety , Cell Count , Embryo Transfer , Female , Gene Expression Regulation, Developmental , Learning , Male , Mice , Mice, Inbred C57BL , MicroRNAs/metabolism , RNA, Messenger/metabolism
4.
Cancer Res ; 75(17): 3596-607, 2015 Sep 01.
Article in English | MEDLINE | ID: mdl-26330166

ABSTRACT

Target-mediated toxicity is a major limitation in the development of chimeric antigen T-cell receptors (CAR) for adoptive cell therapy of solid tumors. In this study, we developed a strategy to adjust the affinities of the scFv component of CAR to discriminate tumors overexpressing the target from normal tissues that express it at physiologic levels. A CAR-expressing T-cell panel was generated with target antigen affinities varying over three orders of magnitude. High-affinity cells recognized target expressed at any level, including at levels in normal cells that were undetectable by flow cytometry. Affinity-tuned cells exhibited robust antitumor efficacy similar to high-affinity cells, but spared normal cells expressing physiologic target levels. The use of affinity-tuned scFvs offers a strategy to empower wider use of CAR T cells against validated targets widely overexpressed on solid tumors, including those considered undruggable by this approach.


Subject(s)
ErbB Receptors/immunology , Neoplasms/immunology , Receptor, ErbB-2/immunology , Receptors, Antigen/immunology , Animals , Cell Line, Tumor , ErbB Receptors/antagonists & inhibitors , Gene Expression Regulation, Neoplastic/immunology , Humans , Immunotherapy, Adoptive , Mice , Neoplasms/drug therapy , Neoplasms/pathology , Receptor, ErbB-2/antagonists & inhibitors , Receptors, Antigen/antagonists & inhibitors , Single-Chain Antibodies/administration & dosage , Single-Chain Antibodies/immunology , T-Lymphocytes/immunology , Xenograft Model Antitumor Assays
5.
Biol Reprod ; 90(2): 26, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24352558

ABSTRACT

Assisted reproductive technologies (ART) have been associated with several adverse perinatal outcomes involving placentation and fetal growth. It is critical to examine each intervention individually in order to assess its relationship to the described adverse perinatal outcomes. One intervention ubiquitously used in ART is superovulation with gonadotropins. Superovulation results in significant changes in the hormonal milieu, which persist during the peri-implantation and early placentation periods. Epidemiologic evidence suggests that the treatment-induced peri-implantation maternal environment plays a critical role in perinatal outcomes. In this study, using the mouse model, we have isolated the exposure to the peri-implantation period, and we examine the effect of superovulation on placentation and fetal growth. We report that the nonphysiologic peri-implantation maternal hormonal environment resulting from gonadotropin stimulation appears to have a direct effect on fetal growth, trophoblast differentiation, and gene expression. This appears to be mediated, at least in part, through trophoblast expansion and invasion. Although the specific molecular and cellular mechanism(s) leading to these observations remain to be elucidated, identifying this modifiable risk factor will not only allow us to improve perinatal outcomes with ART, but help us understand the pathophysiology contributing to these outcomes.


Subject(s)
Embryo Implantation , Fetal Development/drug effects , Gonadotropins/adverse effects , Hormones/blood , Placenta Diseases/chemically induced , Superovulation/blood , Animals , Cellular Microenvironment/drug effects , Cellular Microenvironment/physiology , Embryonic Development/drug effects , Female , Fetal Development/physiology , Gonadotropins/blood , Hormones/pharmacology , Male , Mice , Mice, Inbred C57BL , Placenta/cytology , Placenta/pathology , Placenta Diseases/blood , Placenta Diseases/pathology , Placentation/drug effects , Placentation/physiology , Pregnancy , Signal Transduction/drug effects , Superovulation/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...